Mutational Signature‐Based Biomarker for Phase <scp>II</scp> Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Katsutoshi Oda(The University of Tokyo), Kosei Hasegawa(Saitama Medical University), Masataka Takenaka(Jikei University School of Medicine), Kunihiro Nishimura(National Cerebral and Cardiovascular Center), Keiko Ueda(Japan Society for the Promotion of Science), Yosuke Konno(Hokkaido University of Science), Daisuke Shintani(Saitama Medical University), Masahiro Kagabu(Iwate Medical University), Shiro Takamatsu(The University of Texas MD Anderson Cancer Center), Akira Nishijima(The University of Tokyo), Sho Sato(Saitama Medical University), Shoji Nagao(Hyogo Prefectural Cancer Center), Noriomi Matsumura(Kindai University Hospital), Takashi Aoki(X-Ability (Japan)), Kazuyoshi Kato(Kitasato University Hospital), Hiroyuki Aburatani(The University of Tokyo), Junzo Hamanishi(Kyoto University), Kosuke Yoshihara(Niigata University of Rehabilitation), M Mori(The University of Tokyo), Kenji Tatsuno(The University of Tokyo), Kosuke Kashiwabara(Japan Society for the Promotion of Science)
Cancer Science
May 24, 2026
Cited by 0


Related Papers